1. Home
  2. MTLS vs LCTX Comparison

MTLS vs LCTX Comparison

Compare MTLS & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Materialise NV

MTLS

Materialise NV

HOLD

Current Price

$5.67

Market Cap

356.2M

Sector

Technology

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.68

Market Cap

393.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTLS
LCTX
Founded
1990
1990
Country
Belgium
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
356.2M
393.9M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
MTLS
LCTX
Price
$5.67
$1.68
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$4.25
AVG Volume (30 Days)
150.8K
1.3M
Earning Date
10-28-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.09
N/A
Revenue
$308,751,613.00
$10,816,000.00
Revenue This Year
$2.47
$5.24
Revenue Next Year
$6.98
$126.78
P/E Ratio
$64.58
N/A
Revenue Growth
N/A
24.05
52 Week Low
$3.93
$0.37
52 Week High
$9.69
$2.09

Technical Indicators

Market Signals
Indicator
MTLS
LCTX
Relative Strength Index (RSI) 42.24 46.00
Support Level $5.80 $1.69
Resistance Level $5.89 $1.79
Average True Range (ATR) 0.18 0.08
MACD -0.03 -0.00
Stochastic Oscillator 13.79 43.75

Price Performance

Historical Comparison
MTLS
LCTX

About MTLS Materialise NV

Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: